HALO
Halozyme Therapeutics Inc.

4,878
Mkt Cap
$8.48B
Volume
1.92M
52W High
$79.50
52W Low
$47.50
PE Ratio
15.23
HALO Fundamentals
Price
$72.47
Prev Close
$72.13
Open
$71.98
50D MA
$68.01
Beta
0.69
Avg. Volume
2.13M
EPS (Annual)
$3.43
P/B
16.90
Rev/Employee
$2.9M
Loading...
Loading...
News
all
press releases
HALO or AXSM: Which Is the Better Value Stock Right Now?
HALO vs. AXSM: Which Stock Is the Better Value Option?
Zacks·10h ago
News Placeholder
More News
News Placeholder
TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock
TD Cowen lifted their price objective on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday...
MarketBeat·1d ago
News Placeholder
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab
(RTTNews) - Halozyme Therapeutics, Inc. (HALO), Thursday announced that the company has entered a global collaboration and exclusive license agreement with Takeda, allowing the latter to access...
Nasdaq News: Markets·1d ago
News Placeholder
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE Halozyme Announces Global Collaboration and License Agreement with...
PR Newswire·2d ago
News Placeholder
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells 2,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 2,000 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at...
MarketBeat·3d ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) Director Sells $140,500.00 in Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 2,000 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at...
MarketBeat·3d ago
News Placeholder
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity Halozyme and Skye Bioscience Announce Global...
PR Newswire·5d ago
News Placeholder
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO
Cwm LLC lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2,136.0% during the third quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·6d ago
News Placeholder
Arbor Investment Advisors LLC Invests $1.32 Million in Halozyme Therapeutics, Inc. $HALO
Arbor Investment Advisors LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·7d ago
News Placeholder
Zacks Research Brokers Increase Earnings Estimates for HALO
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report...
MarketBeat·12d ago
<
1
2
...
>

Latest HALO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.